Galectin Therapeutics (GALT) News Today → Protect Your Bank Account Before It’s Too Late (From Weiss Ratings) (Ad) Free GALT Stock Alerts $3.23 +0.09 (+2.87%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 18 at 12:01 AM | seekingalpha.comGalectin Therapeutics GAAP EPS of -$0.19May 15 at 2:12 PM | investorplace.comGALT Stock Earnings: Galectin Therapeutics Misses EPS for Q1 2024May 15 at 8:00 AM | globenewswire.comGalectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2024 and Provides Business UpdateMay 15 at 4:56 AM | americanbankingnews.comGalectin Therapeutics (NASDAQ:GALT) Rating Lowered to Sell at StockNews.comMay 13, 2024 | finance.yahoo.comGalectin Therapeutics to Participate in the H.C. Wainwright BioConnect ConferenceApril 30, 2024 | money.usnews.comGalectin Therapeutics IncApril 26, 2024 | insidertrades.comInsider Selling: Galectin Therapeutics Inc. (NASDAQ:GALT) Major Shareholder Sells 21,323 Shares of StockApril 25, 2024 | marketbeat.comGalectin Therapeutics Inc. (NASDAQ:GALT) Major Shareholder Sells $65,248.38 in StockGalectin Therapeutics Inc. (NASDAQ:GALT - Get Free Report) major shareholder James C. Czirr sold 21,323 shares of the stock in a transaction dated Monday, April 22nd. The stock was sold at an average price of $3.06, for a total transaction of $65,248.38. Following the transaction, the insider now owns 5,925,884 shares of the company's stock, valued at approximately $18,133,205.04. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Major shareholders that own more than 10% of a company's stock are required to disclose their sales and purchases with the SEC.April 20, 2024 | morningstar.comGalectin Therapeutics Inc GALTApril 16, 2024 | marketbeat.comShort Interest in Galectin Therapeutics Inc. (NASDAQ:GALT) Rises By 5.1%Galectin Therapeutics Inc. (NASDAQ:GALT - Get Free Report) was the target of a significant increase in short interest in March. As of March 31st, there was short interest totalling 2,250,000 shares, an increase of 5.1% from the March 15th total of 2,140,000 shares. Approximately 5.3% of the company's stock are short sold. Based on an average trading volume of 105,800 shares, the short-interest ratio is currently 21.3 days.April 11, 2024 | marketbeat.comTraders Purchase Large Volume of Galectin Therapeutics Call Options (NASDAQ:GALT)Galectin Therapeutics Inc. (NASDAQ:GALT - Get Free Report) was the recipient of some unusual options trading on Thursday. Stock traders bought 10,013 call options on the company. This represents an increase of 10,784% compared to the typical daily volume of 92 call options.April 9, 2024 | markets.businessinsider.comGalectin Therapeutics Gets DSMB's Nod To Continue Phase 2b/3 NAVIGATE Study Of BelapectinApril 9, 2024 | marketbeat.comGalectin Therapeutics (NASDAQ:GALT) Earns "Buy" Rating from HC WainwrightHC Wainwright restated a "buy" rating and issued a $11.00 price target on shares of Galectin Therapeutics in a research report on Tuesday.April 9, 2024 | finance.yahoo.comGalectin Therapeutics Reports the Positive Outcome of the Fifth Data and Safety Monitoring Board Meeting for NAVIGATE Phase 2b/3 Study of Belapectin in Patients with Cirrhotic Portal Hypertension Caused by Metabolic Dysfunction-Associated SteatoHepatitisApril 5, 2024 | investorplace.comGALT Stock Earnings: Galectin Therapeutics Meets EPS for Q4 2023April 4, 2024 | marketbeat.comFY2025 Earnings Forecast for Galectin Therapeutics Inc. (NASDAQ:GALT) Issued By HC WainwrightGalectin Therapeutics Inc. (NASDAQ:GALT - Free Report) - Equities research analysts at HC Wainwright lowered their FY2025 earnings per share (EPS) estimates for shares of Galectin Therapeutics in a research note issued to investors on Monday, April 1st. HC Wainwright analyst E. Arce now anticipatApril 3, 2024 | benzinga.comGalectin Therapeutics Stock (NASDAQ:GALT), Analyst Ratings, Price Targets, PredictionsApril 3, 2024 | marketbeat.comAnalysts Set Expectations for Galectin Therapeutics Inc.'s FY2028 Earnings (NASDAQ:GALT)Galectin Therapeutics Inc. (NASDAQ:GALT - Free Report) - Investment analysts at HC Wainwright issued their FY2028 earnings per share estimates for Galectin Therapeutics in a research report issued on Monday, April 1st. HC Wainwright analyst E. Arce expects that the company will post earnings of $April 2, 2024 | markets.businessinsider.comBuy Rating Affirmed for Galectin Therapeutics Amidst Positive Clinical Trial Progress and Enhanced Financial StabilityApril 1, 2024 | marketbeat.comGalectin Therapeutics (NASDAQ:GALT) Lifted to "Hold" at StockNews.comStockNews.com upgraded shares of Galectin Therapeutics from a "sell" rating to a "hold" rating in a research report on Monday.April 1, 2024 | marketbeat.comGalectin Therapeutics (NASDAQ:GALT) Rating Reiterated by HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $11.00 price target on shares of Galectin Therapeutics in a research note on Monday.March 29, 2024 | finanznachrichten.deGalectin Therapeutics Inc.: Galectin Therapeutics Reports 2023 Financial Results and Provides Business UpdateMarch 29, 2024 | msn.comWhat retail stores are open Easter 2024? Details on Walmart, Target, Macy's, Kohl's, moreMarch 29, 2024 | finance.yahoo.comGalectin Therapeutics Inc (GALT) Reports 2023 Financial Results and Business DevelopmentsMarch 29, 2024 | globenewswire.comGalectin Therapeutics Reports 2023 Financial Results and Provides Business UpdateMarch 26, 2024 | marketbeat.comGalectin Therapeutics (NASDAQ:GALT) Stock Price Crosses Above 200-Day Moving Average of $1.89Galectin Therapeutics (NASDAQ:GALT) Stock Price Passes Above 200 Day Moving Average of $1.89March 20, 2024 | seekingalpha.comGalectin: Q4 2024 NASH Cirrhosis Data Readout Is A Major Inflection PointMarch 18, 2024 | marketbeat.comGalectin Therapeutics (NASDAQ:GALT) Downgraded by StockNews.com to SellStockNews.com downgraded Galectin Therapeutics from a "hold" rating to a "sell" rating in a research report on Monday.March 14, 2024 | msn.comMadrigal granted FDA approval for NASH therapyMarch 13, 2024 | msn.comLiver drug developers outperform as U.S. awaits first NASH drugMarch 12, 2024 | globenewswire.comGalectin Therapeutics Expands Clinical Team with the Appointment of Khurram Jamil, M.D. as Vice President, Clinical DevelopmentMarch 7, 2024 | marketbeat.comGalectin Therapeutics (NASDAQ:GALT) Share Price Crosses Above 200 Day Moving Average of $1.85Galectin Therapeutics (NASDAQ:GALT) Stock Price Passes Above Two Hundred Day Moving Average of $1.85February 29, 2024 | seekingalpha.comGALT Galectin Therapeutics Inc.February 21, 2024 | finance.yahoo.comRetail investors account for 55% of Galectin Therapeutics Inc.'s (NASDAQ:GALT) ownership, while insiders account for 21%November 14, 2023 | markets.businessinsider.comArce’s Buy Rating on Galectin Therapeutics: Promising NAVIGATE Trial Progress and Strong Financial OutlookNovember 13, 2023 | msn.comGalectin Therapeutics GAAP EPS of -$0.24November 13, 2023 | benzinga.comGalectin Therapeutics: Q3 Earnings InsightsNovember 13, 2023 | finance.yahoo.comGalectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business UpdateNovember 13, 2023 | finance.yahoo.comUPDATE – Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business UpdateNovember 13, 2023 | finance.yahoo.comGalectin Therapeutics Inc (GALT) Reports Increased Net Loss in Q3 2023November 3, 2023 | finance.yahoo.comGalectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting™ 2023, Hosted by the AASLDOctober 23, 2023 | finance.yahoo.comGalectin Therapeutics to Participate in the H.C. Wainwright 7th Annual NASH Investor Conference on October 24, 2023October 12, 2023 | finance.yahoo.comGalectin Therapeutics Announces Nomination of Dr. Benjamin S. Carson, Sr. to Board of DirectorsOctober 10, 2023 | finance.yahoo.comGalectin Therapeutics Inc. (PHPN.F)October 3, 2023 | finance.yahoo.comGalectin Therapeutics Reports the Positive Outcome of the Fourth Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Portal Hypertension Caused by Non-Alcoholic SteatoHepatitis Liver CirrhosisSeptember 26, 2023 | finance.yahoo.comGalectin Therapeutics to Present Update on its Belapectin Liver Cirrhosis Program at the 20th Edition of Discovery on Target meeting, in Boston, September 25-28, 2023September 14, 2023 | finance.yahoo.comGalectin Therapeutics Inc. (NASDAQ:GALT) surges 16%; individual investors who own 59% shares profited along with insidersSeptember 13, 2023 | finance.yahoo.comGalectin Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference on September 13, 2023September 11, 2023 | finance.yahoo.comGalectin Therapeutics Inc. (GALT)'s Technical Outlook is Bright After Key Golden CrossSeptember 7, 2023 | finance.yahoo.comGalectin Therapeutics to Present Data on Liver Cirrhosis at the 9th Edition of the Paris NASH meeting, at Institut Pasteur, September 7th & 8th 2023 Get Galectin Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GALT and its competitors with MarketBeat's FREE daily newsletter. Email Address [FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks (Ad)Are you monitoring 13,217 cryptocurrencies everyday? If not, you could miss the ONE that can make you wealthy beyond your wildest dreams. You see, while Bitcoin and Ethereum steal all the headlines… It’s often the cryptos flying under the radar that turn small stakes into life-changing windfalls. Claim your free seat by clicking here now. GALT Media Mentions By Week GALT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GALT News Sentiment▼-0.800.53▲Average Medical News Sentiment GALT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GALT Articles This Week▼71▲GALT Articles Average Week Get Galectin Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GALT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: GLSI News ALIM News RIGL News LFCR News GOSS News TELO News CAPR News PRLD News ACRV News SCPH News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GALT) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersMake this ONE trade on Tuesday at 2 p.m. EST!Monument Traders AllianceDems have chosen Biden replacement?Paradigm PressThe Next Industry Being Reshaped By AIThe Bull ReportWhy Is Gold On a MASSIVE rally? Huge AlertsA letter is coming from the "Bureau of the Fiscal Service".Stansberry ResearchShocking $16T Elon Musk Crypto LeakCrypto 101 MediaElon’s New Device is About to Shock the WorldInvestorPlace[URGENT] DO NOT Touch These AI Stocks!Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galectin Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
